New anti-cancer drug extends life of melanoma victims

A new experimental drug developed by Bristol-Myers Squibb and Medarex extends the lives of patients with advanced melanoma, the deadliest form of skin cancer, researchers said.

The results paved the way for dealing with a form of cancer that has few treatment options. Melanoma cases have climbed faster than any other cancer type over the past 30 years, researchers said.

Nearly a quarter - 24 percent - of patients with advanced melanoma survived for an unusual two years after being administered intravenously with ipilimumab.

Forty-four to 46 percent of patients treated with ipilimumab were alive after one year of trials compared to 25 percent of patients treated with other methods, the study pointed out.

"Randomized clinical trials have repeatedly failed to demonstrate an improvement in overall survival in patients with advanced melanoma," said lead author Steven O'Day, who heads the melanoma program at The Angeles Clinic and Research Institute in southern California.

O'Day described the study findings as "an exciting advance, both for patients with advanced melanoma and for the field of cancer immunology."

He presented the study at the American Society of Clinical Oncology meeting this weekend in Chicago.

Lynn Schuchter, professor of medicine at Abramson Cancer Center at the University of Pennsylvania, said these findings were "really exciting" because ipilimumab and other new cancer drugs produced far fewer side effects than traditional chemotherapy.

"This drug takes the brake off and allows for further immunological response, and this is going to be the first time that a trial with patients with advanced melanoma shows a survival benefit," Schuchter said.

She noted that just six months ago, doctors really had no effective therapy for patients with stage 4 melanoma.

Ipilimumab belongs to a new class of drugs that activate the immune system's T cells, which then seek and destroy melanoma cells, instead of targeting the cancer cell itself like previous treatments.

In the clinical test, patients who took ipilimumab or were treated with a combination of the antibody and a peptide vaccine, also aimed at boosting the immune system, lived a median of 10 months, against 6.5 months for those administered a placebo or a peptide vaccine alone.

The Phase III clinical trial studied some 600 melanoma patients in several countries. Patients generally tolerated the treatment well, the researchers said.

Experts pointed out that given the success of the trials, the US Food and Drug Administration was expected to grant permission to market the medicine relatively quickly.

Ipilimumab was forecast to generate more than 400 million dollars in sales in the first several years following its approval.

Melanoma is one of the deadliest forms of cancer, and the number of people affected by it has been increasing for 30 years, according to the World Health Organization.

Skin cancer annually kills 66,000 people around the world, the WHO said, and 80 percent of these deaths are attributable to melanoma.

As many as 68,000 new cases of melanoma were diagnosed in the United States last year, and about 8,600 people died of the disease.

In France, 7,000 cases of melanoma are detected each year, and an average of 1,300 of them have a fatal outcome.

News
news
Sport
Danny Cipriani of England breaks clear to score his second try
rugby
Life and Style
New research says leaving your desk can help you to avoid serious illness
health
Arts and Entertainment
tvSPOILER ALERT: Like a mash-up of 28 Days Later, Braveheart, The Killing and Lord of the Rings, this GoT episode was a belter
Life and Style
ebookNow available in paperback
ebooks
ebookA delicious collection of 50 meaty main courses
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: Graduate Trainee

    £15000 - £20000 per annum: Recruitment Genius: This Cloud ERP Solution Provide...

    Recruitment Genius: Business Development Executive / Digital Marketing Executive

    £26000 - £35000 per annum: Recruitment Genius: A luxury beauty house with a nu...

    Recruitment Genius: Housekeepers - Immediate Start

    £8 per hour: Recruitment Genius: This company are currently recruiting new exp...

    Recruitment Genius: Head Concierge

    £25000 - £28000 per annum: Recruitment Genius: This award winning Property Man...

    Day In a Page

    On your feet! Spending at least two hours a day standing reduces the risk of heart attacks, cancer and diabetes, according to new research

    On your feet!

    Spending half the day standing 'reduces risk of heart attacks and cancer'
    Liverpool close in on Milner signing

    Liverpool close in on Milner signing

    Reds baulk at Christian Benteke £32.5m release clause
    With scores of surgeries closing, what hope is there for the David Cameron's promise of 5,000 more GPs and a 24/7 NHS?

    The big NHS question

    Why are there so few new GPs when so many want to study medicine?
    Big knickers are back: Thongs ain't what they used to be

    Thongs ain't what they used to be

    Big knickers are back
    Thurston Moore interview

    Thurston Moore interview

    On living in London, Sonic Youth and musical memoirs
    In full bloom

    In full bloom

    Floral print womenswear
    From leading man to Elephant Man, Bradley Cooper is terrific

    From leading man to Elephant Man

    Bradley Cooper is terrific
    In this the person to restore our trust in the banks?

    In this the person to restore our trust in the banks?

    Dame Colette Bowe - interview
    When do the creative juices dry up?

    When do the creative juices dry up?

    David Lodge thinks he knows
    The 'Cher moment' happening across fashion just now

    Fashion's Cher moment

    Ageing beauty will always be more classy than all that booty
    Thousands of teenage girls enduring debilitating illnesses after routine school cancer vaccination

    Health fears over school cancer jab

    Shock new Freedom of Information figures show how thousands of girls have suffered serious symptoms after routine HPV injection
    Fifa President Sepp Blatter warns his opponents: 'I forgive everyone, but I don't forget'

    'I forgive everyone, but I don't forget'

    Fifa president Sepp Blatter issues defiant warning to opponents
    Extreme summer temperatures will soon cause deaths of up to 1,700 more Britons a year, says government report

    Weather warning

    Extreme summer temperatures will soon cause deaths of up to 1,700 more Britons a year, says government report
    LSD: Speaking to volunteer users of the drug as trials get underway to see if it cures depression and addiction

    High hopes for LSD

    Meet the volunteer users helping to see if it cures depression and addiction
    German soldier who died fighting for UK in Battle of Waterloo should be removed from museum display and given dignified funeral, say historians

    Saving Private Brandt

    A Belgian museum's display of the skeleton of a soldier killed at Waterloo prompts calls for him to be given a dignified funeral